Safety Alerts & Recalls
What does this mean?
Although the results from the SEAS study raise concerns about a possible link between Vytorin and cancer, several other larger ongoing trials do not show an increased risk of cancer with Vytorin. The FDA expects to release a final review about the safety of Vytorin in about 9 months. Based on the currently available information, the FDA has determined that patients should continue to take Vytorin or any other cholesterol-lowering drug.
FDA Is Reviewing Results From a Recent Clinical Trial of Vytorin
The FDA announced that it is reviewing the results of the "SEAS" trial - a clinical study that raised concerns about the risk of cancer in patients taking Vytorin compared with those given a placebo. Vytorin is a combination of two medications, simvastatin (Zocor) and ezetimibe (Zetia) and is used to lower cholesterol.
For more information please visit: more information here